Modulation of cytokine production by 7-hydroxycoumarin in vitro and its efficacy against influenza infection in mice

Antiviral Research
Masahiko KurokawaKimiyasu Shiraki

Abstract

We previously demonstrated that 7-hydroxycoumarin (7HC) was effective in reducing proinflammatory cytokine production in lipopolysaccharide-exposed macrophage-like P388D1 cells and fever production by suppressing the increase in interleukin (IL)-1alpha production in an influenza virus-intranasal infection model in mice. In this study, we assessed the effects of modulation of cytokine production by 7HC on influenza virus infection in relation to its efficacy in influenza virus-infected mice. 7HC was confirmed to suppress proinflammatory cytokine levels in P388D1 cells due to influenza virus infection. In the murine infection model, oral administration of 7HC (30 mg/kg) was significantly effective in reducing the weight loss of infected mice and virus titers in the bronchoalveolar lavage fluid (BALF) of lungs and in prolonging survival times without toxicity. The rise of proinflammatory and Th1 cytokine (IL-12 and interferon-gamma) production in the BALF from infected mice was significantly suppressed by 7HC at two and four days post-infection, respectively. This suppression correlated with the reduction of virus titers and diminution of lung consolidation. Because 7HC did not exhibit direct anti-influenza virus activity in vitro...Continue Reading

References

Nov 1, 1991·Proceedings of the Society for Experimental Biology and Medicine·H Maeda, T Akaike
Sep 1, 1990·The Journal of General Virology·M KurokawaS Niwayama
Jan 28, 1994·Cell·W E Paul, R A Seder
Oct 1, 1996·Journal of Medical Virology·M KurokawaK Shiraki
Mar 28, 1998·American Journal of Respiratory and Critical Care Medicine·K SatoM Ando
Jan 9, 1999·Molecular Immunology·S E BarbourA D Carter
Sep 9, 1999·The Journal of Infectious Diseases·B P ArulanandamD W Metzger
May 9, 2000·Veterinary Microbiology·K Van Reeth
Jun 26, 2001·Journal of Medical Virology·L KaiserF G Hayden
Aug 19, 2003·European Journal of Pharmacology·Masahiko KurokawaKimiyasu Shiraki
Feb 28, 2004·Lancet·J S M PeirisY Guan
Dec 14, 2004·Drugs·Jack Ansell, David Bergqvist
Aug 19, 2006·American Journal of Respiratory and Critical Care Medicine·Tong XuChanggui Dong
Dec 22, 2006·Journal of Virology·Kristy J SzretterJacqueline M Katz
Jul 10, 2008·Antiviral Chemistry & Chemotherapy·Tomomi ShimizuMasahiko Kurokawa

❮ Previous
Next ❯

Citations

Mar 23, 2011·Journal of Natural Products·Flávia Oliveira de LimaCristiane Flora Villarreal
Jul 9, 2013·Bioscience, Biotechnology, and Biochemistry·Shiro TakedaMasahiko Kurokawa
Oct 20, 2011·Immunological Investigations·Tsvetanka StefanovaGerhard Zlabinger
Mar 29, 2011·Expert Opinion on Pharmacotherapy·Paolo Preziosi
Oct 10, 2014·Journal of Pharmacological Sciences·Tohru DaikokuKimiyasu Shiraki
Dec 24, 2011·Journal of Ethnopharmacology·Qiao-feng WuChen-huan Yu
Sep 3, 2013·Chemico-biological Interactions·Luciana M KabeyaYara Maria Lucisano-Valim
Nov 4, 2010·Antiviral Chemistry & Chemotherapy·Rie SawamuraMasahiko Kurokawa
Jun 22, 2021·Future Journal of Pharmaceutical Sciences·A Brindha Devi, R Sarala

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.